Celgene Corp
CELG:NASDAQ
| 最新 | 变化/%变化 | 股息收益率 | 交易量 | Avg Volume (10 day) |
| 111.90 | 0.00 0.00% | 0.00% | 0 | 3.6M |
市场数据至少延迟20分钟
Celgene Corp的最新新闻标题
Amarin, Celgene, GlaxoSmithKline, Spectrum Pharma, and Geron Briefing and Review
The healthcare industry is evaluating the impact of President Obama's Affordable Care Act (ACA) on their businesses. While critics of the healthcare reform say that the ACA will result in higher costs for healthcare companies, supporters of the reform point out the long-term benefits to the industry which include players such as Amarin Corporation Plc (NASDAQ: AMRN), Celgene Corporation (NASDAQ: CELG), GlaxoSmithKline Plc (NYSE: GSK), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) and Geron Corporation (NASDAQ: GERN). On Friday, healthcare stocks ended mostly lower, tracking losses in the broad market. StockCall has released free charting and technical research on these aforementioned companies. Register to read these reports at
Next Support Level for Celgene (CELG) is $110.99
Shares of Celgene (NASDAQ:CELG) have bearishly opened below the pivot of $112.99 today and have reached the first support level of $111.70. Analysts will be watching for a cross of the next downside pivot targets of $110.99 and $108.99.
Upcoming Results from Clinical Trials - Research Report on Gilead Sciences, Celgene Corporation, Sinovac Biotech, NPS Pharmaceuticals and ZIOPHARM Oncology
查看更多最新标题Today, Wall Street Source announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Sinovac Biotech Ltd. (NASDAQ: SVA), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
公司背景
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
买方价/量 -- / -- | 卖方价/量 -- / -- |
开盘价格 0.00 | 前收盘价格 111.90 |
当天最高 0.00 | 当天最低 0.00 |
52周高/日期 115.44 / 3/14/2013 | 52周低/日期 58.53 / 6/21/2012 |
% off 52wk High -3.07% | % off 52wk Low 91.18% |
贝他(5年) 0.7 | 市值 46.9B |
流通股数 418.7M | 波动平均(Volatility Avg) 27.96 |
每股收益(EPS)(TTM) 3.30 | 市盈率(P/E) 33.9x |
股息宣布日 -- | 股息收益率 0.00% |
除息日 -- | 登记日 -- |
支付数额 0.00 - -- | 支付日期 -- |
上次交易3/18/2013 4:00 PM ET | |
CELG Celgene Corp 对比同行
| 同行 | |
|---|---|
CELG Celgene Corp | 42.60% |
Amgen, Inc. | 4.86% |
Biogen Idec Inc. | 19.92% |
Bristol Myers Squibb Co. | 19.30% |
Johnson & Johnson | 12.43% |
CELG Celgene Corp | 0.00% |
Amgen, Inc. | 2.08% |
Biogen Idec Inc. | -- |
Bristol Myers Squibb Co. | 3.60% |
Johnson & Johnson | 3.10% |
CELG Celgene Corp | 0.00% |
Amgen, Inc. | 0.00% |
Biogen Idec Inc. | 0.00% |
Bristol Myers Squibb Co. | 0.00% |
Johnson & Johnson | 0.00% |